
CPI Cools: Could Fed Rate Cuts Spark A Growth Stock Surge?
Traders are seen in the oil futures pit (foreground), 29 October 2007, at the New York Mercantile ... More Exchange as prices continue to rise. US shares posted moderate gains Monday as investors banked on a Federal Reserve interest rate cut this week and oil prices hit new highs. The Dow Jones Industrial Average was up 28.93 points (0.21 percent) to 13,835.63 around 1505 GMT and the tech-heavy Nasdaq added 2.91 points (0.10 percent) to 2,807.10. AFP PHOTO/Stan HONDA (Photo credit should read STAN HONDA/AFP via Getty Images)
The Consumer Price Index (CPI) came in at 0.1% for May — lower than the expected 0.2%. This softer-than-expected reading was driven by notable declines in energy prices, used cars, transportation services, and apparel. However, the most promising takeaway lies beneath the surface.
Shelter costs — which account for nearly one-third of the CPI and typically act as a lagging indicator — have not yet shown a meaningful slowdown. Despite falling real estate prices across major U.S. cities like San Francisco, Austin, Tampa, and Phoenix, shelter still posted a 0.3% month-over-month increase. This is significant: once this category begins reflecting broader price declines, headline inflation could fall more sharply.
Why does this matter? The Federal Reserve may respond. Analysts currently expect two rate cuts before year-end, but a third or even fourth cut could be on the table if inflation trends lower and economic growth remains sluggish.
The June 17–18 Fed meeting is unlikely to bring immediate action, but upcoming meetings in July, September, November, and December remain live. Adding to the pressure is the widening gap between the U.S. Fed Funds Rate and the European Central Bank (ECB) rate — now more than 225 basis points apart — which is likely to draw criticism from President Trump and other policymakers.
Could the Fed cut in July? Probably not. But if they even hint that cuts are being reconsidered, markets could surge. The effect of rate cuts on equity markets is often more powerful than other leading indicators. Growth stocks in particular are poised to benefit.
Historically, summer is a quiet period for equities — and May is traditionally a weak month ("sell in May and go away"). Yet this year, markets rallied strongly in May. If the inflation trend continues and geopolitical risks like tariffs do not materialize, we may be headed toward an unexpected summer rally — with multiple rate cuts fueling the momentum.
-------------------------
Disclosure: Past performance is no guarantee of future results. Please refer to the following link for additional disclosures: https://lnkd.in/e29X6rN
Additional Disclosure Note: The author has an affiliation with ERShares and the XOVR ETF. The intent of this article is to provide objective information; however, readers should be aware that the author may have a financial interest in the subject matter discussed. As with all equity investments, investors should carefully evaluate all options with a qualified investment professional before making any investment decision. Private equity investments, such as those held in XOVR, may carry additional risks—including limited liquidity—compared to traditional publicly traded securities. It is important to consider these factors and consult a trained professional when assessing suitability and risk tolerance.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Financing to provide $11.5 million in upfront proceeds with up to an additional $10.4 million of proceeds assuming exercise in full of the warrants Financing priced at a premium to last close SOUTH SAN FRANCISCO, Calif., June 12, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX) ("Quince" or the "Company"), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors to purchase shares of its common stock (or pre-funded warrants in lieu thereof), and accompanying common warrants ("Warrants") that is expected to result in approximately $11.5 million in upfront proceeds and potential additional proceeds of up to $10.4 million if the accompanying common warrants are exercised in full for cash, before deducting placement agent fees and other private placement expenses. The private placement is being led by healthcare-focused institutional investor Nantahala Capital with participation from existing Quince stockholders including ADAR1 Capital Management, along with members of Quince's senior management. Quince intends to use the net proceeds of this offering for working capital and general corporate purposes, including funding the ongoing enrollment of the Company's pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial in Ataxia-Telangiectasia (A-T), research and development expenses, general and administrative expenses and capital expenditures. The net upfront proceeds from the private placement, combined with Quince's current cash, cash equivalents, and short-term investments are expected to fund the Company's operations into the second quarter of 2026, or the second half of 2026 if the Warrants are exercised in full for cash. At the closing, the Company will issue to the investors an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), along with accompanying Warrants to purchase an aggregate of 8,671,928 shares of common stock (or pre-funded warrants in lieu thereof), at a combined purchase price of $1.325 per share (or $1.324 per pre-funded warrant) and accompanying Warrant (representing a 10% premium over the $1.20 closing price per share of the Company's common stock). The accompanying Warrants have an exercise price of $1.20 per share and will become exercisable immediately. The Warrants will expire five years from the date of issuance. The private placement is expected to close during the week of June 16, 2025, subject to the satisfaction of customary closing conditions. Citizens Capital Markets is acting as the lead placement agent for the private placement. Maxim Group LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, are acting as co-placement agents for the private placement. The securities to be issued in connection with the private placement described above are being offered in a private placement and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdictions' securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Quince Therapeutics Quince Therapeutics, Inc. (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. For more information on the company and its latest news, visit Forward-looking Statements Statements made in this news release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this news release regarding the expected closing of the private placement; the receipt of additional gross proceeds if the accompanying common warrants are exercised in full; the achievement of positive clinical trial results and approval of the eDSP by the FDA; the company's intended use of the proceeds from the private placement; the company's expectation that the net proceeds from the closing of the private placement, combined with its current cash, cash equivalents and marketable securities, will fund its operating and capital expenditures into the second quarter of 2026, or the second half of 2026, assuming all warrants are exercised for cash; and the company's strategy, future operations, future financial position, projected expenses, expected timing and results of clinical trials, prospects, plans and objectives of management constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to: cost, timing, progress and results of the pivotal Phase 3 NEAT clinical trial in A-T indication and potential future trials in other indications; the company's ability to obtain FDA approval and successfully commercialize its product candidate; the satisfaction of customary closing conditions related to the proposed private placement and the impact of general economic, industry or political conditions in the United States or internationally, the current or evolving effects of macroeconomic conditions, on Quince's business operations and activities. There can be no assurance that the company will be able to complete the proposed private placement on acceptable terms, or at all. Quince's actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of Quince's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of its Quarterly Reports on Form 10-Q and in the company's other filings with the SEC. Quince undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. View source version on Contacts Media & Investor Contact: Stacy RoughanQuince Therapeutics, President, Corporate Communications & Investor Relationsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Miami Herald
7 minutes ago
- Miami Herald
Popular nationwide beauty chain files for Chapter 11 bankruptcy
The beauty industry has faced economic challenges and financial distress over the last five years since the Covid-19 pandemic temporarily derailed most retail industries. Companies have dealt with rising labor and product costs exacerbated by inflation, increased interest rates, cautious consumers who are watching their budgets in uncertain economic times, and fierce competition. Don't miss the move: Subscribe to TheStreet's free daily newsletter Some of the biggest names in the beauty business suffered from the Covid-19 fallout and filed for bankruptcy protection, including Revlon, which filed for Chapter 11 bankruptcy in June 2022, and Avon, which filed for Chapter 11 bankruptcy in August 2024. Related: Popular local Dairy Queen rival files for Chapter 11 bankruptcy Beauty technology company Cutera filed for a prepackaged Chapter 11 bankruptcy on March 5, 2025, to reduce its debt by $400 million, and award-winning cosmetics company SBLA Beauty filed for Chapter 11 protection on March 11, 2025, to reorganize its business and restructure its debt. Also, telehealth company Hims & Hers Health shut down its acne treatment dermatology business, Apostrophe, also on March 7, 2025, after buying the San Francisco-based company four years ago for about $190 million. The company, however, did not file for bankruptcy protection. Hims & Hers transitioned away from the Apostrophe brand and encouraged patients to try its brand's treatment options, the company revealed on its website. Another skincare brand Futurewise Inc. revealed that it discontinued orders on its website beginning March 24, 2025. "Goodbye for now," the skincare brand wrote on its website. "After a lot of thought, we have made the hard decision to sunset Futurewise. Futurewise, which offered its skincare products Slug Boost, Slug Cream, Slug Balm, and Face Melt, for its "slugging" practice of skincare, also did not file for bankruptcy. In addition to skin care products, spa services for weight loss, non-surgical body improvements, slimming, and toning are also a major part of the beauty industry. One beauty service chain in Tuscaloosa, Ala., faced severe financial issues, filed for bankruptcy, and closed its business. Medical spa Body Oasis filed for bankruptcy on Nov. 6, 2024, and shut down all of its operations, reportedly leaving customers in limbo, ABC-33/40 News reported. Finally, national spa services chain Contour Spa LLC filed for Chapter 11 bankruptcy protection to reorganize its business, facing significant debt obligations. Related: Huge auto parts company files for Chapter 11 bankruptcy The Orlando, Fla.-based company filed its petition in the U.S. Bankruptcy Court for the Middle District of Florida on June 11, while at least 23 affiliates filed their petitions the following day. More bankruptcy: Iconic auto repair chain franchise files Chapter 11 bankruptcyPopular beer brand closes down and files Chapter 7 bankruptcyPopular vodka and gin brand files for Chapter 11 bankruptcy The debtor listed $500,000 to $1 million in assets and $1 million to $10 million in liabilities in its petition, including over $562,000 owed to Lanco Equities, over $344.000 owed to Kash Advance LLC, over $339,000 owed to Formentera Capital Group, over $377,000 owed to Liberta Funding LLC, and over $239,000 owed to American Express. The company has authorized CEO Roger A. Farwell to seek approval of a debtor-in-possession financing agreement, according to RK Consultants. Contour Spa offers its Cryo Slimming sessions using its slimming and toning protocols designed to reduce cellulite, tighten skin, achieve permanent fat loss, and minimize stretch marks. The spa service also offers its Cryo Facials, which can be obtained for free through its $99 introductory offer, according to its website. Related: Major trucking company files Chapter 11 bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.


TechCrunch
10 minutes ago
- TechCrunch
After a string of successes, early-stage fund Felicis raises fresh $900M
In Brief Felicis founder Aydin Senkut is celebrating his 20th year as an institutional early-stage investor by announcing the firm's biggest fund yet: a $900 million Fund X. This follows the $825 million Fund IX raised in 2023 and the $600 million Fund XIII raised in 2021. Felicis, a seed and Series A firm, is known for backing a long string of successes, including Ayden, Bonobos, Ring, Shopify, and Twitch, among others. Since being founded in 2006, Felicis has backed over 50 unicorns and had over 125 exits, it says. Lately, Felicis, like most VCs, has been all over AI. Its portfolio now includes, for example, Browser Use, Poolside, Runway, and Supabase. 'We believe dozens of $100B+ AI companies will emerge this decade (not merely $1B or $10B),' Felicis wrote in its blog post, adding that 70% of its active portfolio are what it considers AI native startups. Senkut did not immediately respond to a request for additional comment.